Introduction: Despite the life-prolonging effects of Highly Active Antiretroviral Therapy (HAART), persons with HIV are still prone to higher rates of non-AIDS related morbidity (such as heart, kidney, and liver disease) than the general public. This is likely due to chronic immune activation and inflammation that persists in HIV-positive persons despite virological suppression.
Introduction and background
By and large, highly active antiretroviral therapy (HAART) has been a resounding success in the management of HIV. While in the past, an HIV diagnosis meant that eventual immunodeficiency was a virtual certainty, viral replication can now be effectively controlled with viral load decrease below the level of detection in most cases (with strict drug compliance), and ten-year survival probabilities are now 78% (according to one 2016 meta-analysis) for patients on HAART [1] .
As HIV infection shifts from a fatal infection to a chronic, lifelong condition, so do the challenges surrounding its management. People living with HIV, even with undetectable viral loads, still face higher rates of morbidity than those who are HIV-negative; for example, those living with HIV experience higher rates of heart disease, neurocognitive decline, osteoporosis, as well as liver and kidney disease than the general public [2] . Research into the mechanisms resulting in higher end-organ dysfunction may provide targets for future interventions.
The link between HIV pathogenesis and chronic immune activation has long been a subject of intense investigation; it has been shown in multiple studies that even when HIV-positive persons have achieved total viral suppression, some circulating markers of inflammation and immune activation remain elevated vis-à-vis HIV-negative persons [3] . A 2008 review by Alfano et al. speculated on the role for cytokines including IL-7, IL-15, IL-17, IL-18, IL-19, IL-20, IL-21, IL-23, and IL-27 in mitigating HIV replication and disease pathogenesis as well as their potential involvement in managing immune reconstitution in HIV-infected individuals [4] . More recently, Wada et al. (2015) identified seven serologic biomarkers of inflammation that remained persistently high in HIVsuppressed men: CXCL10, sCD27, TNFR2, TNF-a, BAFF, CD14, and CRP; seven more were detected at levels significantly different from those in HIV-negative men (gp130, IL-8, CCL13, GM-CSF, and IL-12p70) [3] . Regidor et al. showed that levels of IL-6 and CRP were unaffected by HAART initiation in HIV-positive men, while sCD27, sCD30, IgG, IgA, and CXCL13 decreased but did not normalize to HIV-negative levels [5] . Kamat et al. have posited that a constellation of CXCL9, CXCL10, sIL-2R, and sCD14 may have utility as a plasma biomarker for monitoring immune activation in patients with and without suppressed viremia on HAART [6] .
It is thought that immune activation and chronic subclinical inflammation is driven by persistent microbial translocation across the gut wall, which is initiated after gut epithelium injury early in the disease course, and is able to continue due to incomplete repair even in patients started on HAART [2] . Furthermore, it has been suggested by several studies that this inflammation is linked to poor clinical outcomes [7, 8] . What remains unknown, however, is whether this inflammation and immune activation is linked with poor immune recovery (defined in our study as CD4:CD8 ratio <1), itself a surrogate laboratory marker for poor outcomes [9, 10] .
The hypothesis of the present study is that higher levels of systemic subclinical inflammation and immune activation in patients on HAART are linked with poor immune recovery (represented by CD4:CD8 ratio). The hope is that by identifying a specific constellation of inflammatory and immune activation markers that are linked with eventual poor immune recovery, we can select potential targets for adjunct therapies to HAART that could play a role in reducing the morbidity faced by people living with HIV.
Materials and methods

Population and setting
Fifteen eligible participants were selected from a cohort of 40 treatment-naïve HIV patients who were enrolled in this prospective cohort study and followed for between one to two years. Patients were recruited from an HIV outpatient clinic in a tertiary care hospital in Winnipeg, Canada. All participants receive ongoing care through the Manitoba HIV program, a dual-centre program currently providing care to approximately 1100 Manitobans. We aimed to follow patients for one year with four total visits/sample collections spaced evenly apart (approximately three months) in order to monitor inflammatory response and immune activation over time; frequent missed appointments by patients caused us to extend the time between visits, with the greatest time between first and fourth (last) visit extending to two years.
Inclusion criteria dictated that a patient must have achieved an undetectable viral load (considered <50 copies per ml) by their final recorded visit with the clinical team in order to control for the effect of HAART non-compliance on inflammatory marker expression. Of the 40 total enrolled patients, only 15 met the above criteria within the bounds of our timeline. Patients were enrolled after being linked to care following an HIV diagnosis and just prior to the commencement of HAART under the Manitoba HIV program.
The condition of poor immune response was defined according to CD4:CD8 ratio because it is a more sensitive predictor of future adverse outcomes than the traditional CD4+T cell count [10] . We considered patients who failed to achieve a CD4:CD8 ratio P1 by the time they first achieved virological suppression (<50 copies/ ml) to be poor immunologic responders.
All blood draws and clinical visits were conducted at the Health Sciences Centre (HSC) Internal Medicine Clinic. Table 1 lists baseline characteristics for the 15 enrolled participants.
Ethics statement
This study was approved by the ethics committees of the University of Manitoba and HSC.
Cytokine/chemokine bead-based assays
Cell-free supernatants were aliquoted, and frozen at À80°C. Two multiplex bead-based fluorescent assays were performed on 52 plasma samples (4 different timepoint samples for each of the 15 enrolled participants) to quantify 21 markers of immune activation and inflammation. The inflammatory markers, all found in commercially available kits, were selected based on those exam- mixed all in one vial, 50 ll of the beads' suspension were used in each reaction, samples were diluted 1:4, and run simultaneously. Prior to each assay, calibration and validation were performed. The assays were performed following manufacturers' instructions, respectively, using 50 ll of samples and standards, in duplicates.
The standards were reconstituted and serially diluted as per manufacturer's protocol to generate standard curves. Standards included all recombinant cytokines tested and were considered as positive controls for the procedure. Results were run on a Bioplex 200 instrument (Bio-Rad, Mississauga, ON), reported as mean fluorescence intensity and converted to pg/ml using the Bio-Plex Ò Manager version 6.0) (Bio-Rad, Mississauga, ON).
Statistical analysis
The overarching purpose of the statistical analysis was to determine whether there was an observable difference in concentration of multiple cytokines in patients with good compared to poor immune recovery both at the time when undetectable viral load (<50 copies per ml) was first achieved, and also throughout 4 visits representing the first one to two years of clinical management on HAART.
Principal component analysis (PCA) was conducted using collected cytokine data from all patients at the point of earliest undetectable viral loads to determine which cytokines most contributed to the variability in the data set at that time. Component extraction was achieved using the principle axis method, and the rotation method employed was a Varimax rotation with Kaiser normalization. In interpreting the PCA, an inflammatory marker was considered to load on a given component if the loading factor was 0.6 or greater for that component and less than 0.6 for all other components. By using PCA, we could analyze all cytokines simultaneously, to determine whether a particular constellation of cytokines, when considered together (i.e. those which loaded onto a common component at a given rotation) were disproportionately responsible for the total observed variation in the data set even if statistical significance was unfruitful when individual cytokines were compared in isolation.
Following PCA, paired boxplots were constructed comparing concentrations for each inflammatory marker at viral suppression for good versus poor recovery groups and Mann-Whitney U tests (a = 0.05) were conducted on the cytokines that loaded into each component to determine if they tended to preferentially segregate into the good immune recovery or poor immune recovery group.
To observe, qualitatively, how concentrations of cytokines changed within and across the groups over time, average concentrations of each cytokine were compared for the good and poor immune recovery groups at each of the four time points. 95% confidence intervals were used for each.
Finally, Ingenuity Pathway Analysis (IPA) was used to determine whether the identified cytokines of interest, as determined by the above methods, shared involvement in any networks or canonical pathways, or implied the involvement of any welldescribed physiologic or pathophysiologic processes. The background reference set used for p-value calculations was set to include only human genes listed in the Ingenuity Knowledge Base (IKB), and to exclude endogenous chemicals and genes described only in other species.
All statistical analysis, excluding IPA, was carried out using IBM SPSS Ò version 21.1.1.
Results
PCA, shown in Table 2 , revealed two principal components or rotations of our 21-dimension data set accounting for an accumulated 42.526 percent of the total existing variation. Component 1 accounted for 22.031 percent of the total variation; component 2 accounted for 20.495 percent of the total variation. Of the 21 proinflammatory markers measured in this study, five loaded onto component 1 (IL-27, IFN-g, IL-6Ra, Osteopontin, and gp130) and four markers loaded onto component 2 (TNF-R1, Chitinase 3-like-1, APRIL/TNFSF13, BAFF/TNFSF13B). The remaining four principal components accounted for progressively less variability in the data set and two or fewer proinflammatory markers loaded onto each. IL-34, IL-26, and IL-11 do not appear in the output because they all have the same variance across both poor and good immune responders (the same concentration was detected on each sample for these cytokines).
Mann-Whitney U tests were conducted for each individual proinflammatory marker, comparing cytokine concentrations between good and poor immune recovery groups at the point of initial virological suppression. Despite the PCA results, no proinflammatory marker in isolation achieved statistically significant difference in concentration between the good immune recovery and poor immune recovery groups with an a = 0.05.
However, when the complete distribution of the data is represented as seen in Fig. 1 , a trend toward increased concentrations in poor responders compared to good immune responders is observed in the following proinflammatory markers: IFN-, IL-10, CD163, IFN-a2, IL-32, Osteopontin, BAFF, and APRIL. The effect is most pronounced in BAFF, APRIL, IFN-, and IL-32, where the median concentration for poor responders is above the interquartile range (IQR) for good responders (and for APRIL and BAFF, aside from one outlier each, it is above the maximum value for good responders). Conversely, a trend toward increased concentrations in good responders is observed in the following markers: CD14, TNF-R2, gp130, IL-6Ra, TNF-R1, Chitinase 3-like-1, IL-20, and Osteocalcin. The observed difference in median value is marginal, except in gp130, and IL-6Ra, where the median concentration for good responders exceeds the IQR for poor responders.
Longitudinal data collection at 4 timepoints per patient allowed for the simultaneous observation of how proinflammatory marker concentrations changed over time within a group and how the concentrations of each marker compared between the two groups over time. Fig. 2 depicts the average concentration of proinflammatory markers for both poor and good recovery groups at all four visits. Five markers (TNF-R1, CD163, APRIL, BAFF, and Osteopontin (SPP1)) were observed in higher concentrations across all four timepoints, including at enrollment, prior to HAART initiation, in patients with poor CD4:CD8 recovery; of those five, four (APRIL, BAFF, Osteopontin, and TNF-R1) appeared in the first two PCA components (the two principal components that accounted for the biggest variance between groups). Another five markers (IL-6Ra, Chitinase 3-like-1, IFN-a2, IL-20, and Osteocalcin) were persistently elevated in patients with good CD4:CD8 recovery; of those, only two, IL-Ra and Chitinase 3-like-1, appeared in the first two PCA rotations. Thus, of the nine cytokines in the first two PCA rotations, (that is, the two rotations accounting for an accumulated 42.526 percent of the variability in the data set), six were consistently (at all four visits) found to be on average higher or lower in either the good or poor immune recovery groups. The cytokines in the first two components that did not consistently have higher averages in one immune recovery group over the other (i.e. at all four visits) were IFN-g, IL-27, and gp130. IFN-g was comparable across groups at the first and last visits, but diverged at visit 2. IL-27 was consistently higher on average in those with good recovery except at visit 3, and gp130 was higher on average in those with good recovery at all visits except for visit 2.
In addition, CD14 was observed at a higher mean concentration at every visit except for visit 2; TNF-R2 concentrations were higher in those with poor recovery at the first and last visits, but at the second and third visits, those with good recovery had higher average concentrations.
Ingenuity Pathway Analysis was used to determine whether important molecules in our dataset were overrepresented in previously described networks or canonical pathways. An IPA analysis was conducted to compare functions, relations, and canonical pathway overlap for molecules that were found to be elevated in the poor immune recovery group at all four visits (TNF-R1, CD163, APRIL, BAFF, Osteopontin/SPP1). Three of these molecules, APRIL, BAFF, and TNF-R1 were also present in the second principle component rotation (and one, Osteopontin/SPP1, in the first rotation). According to Ingenuity Knowledge Base (IKB) output, the shared functions/disease implications of these cytokines include rheumatic disease (all five are involved, p-value 2.22 Â 10 À11 ) and all affect the ''proliferation of cells," again this network involving all five markers (p-value 1.31 Â 10 À10 ). There is marginal overlap with canonical pathways -''altered T and B cell signaling in rheumatoid arthritis" (p-value 7.21 Â 10 À7 ) has 3.7 percent overlap with the input data set, while ''communication between innate and adaptive immune cells" has 2.4 percent overlap (p-value 1.7 Â 10 À4 ). A network demonstrating known direct and indirect interactions between the five molecules in the input data set is shown in Fig. 3 .
Proinflammatory markers elevated in all four visits in the good recovery group compared to the poor recovery group (IL-6Ra, Chitinase 3-like-1, IFN-a2, IL-20, and Osteocalcin) were also entered into IPA for analysis. A different set of networks and functions/canonical pathways was detected. Top involved network functions included ''hematological system development and function and tissue morphology" (p-value 5.83 Â 10 À9 ) and ''cellular growth and proliferation" (p-value 2.46 Â 10
À8
) although none of the identified pathways incorporated all five of the molecules in the input dataset.
Discussion
Identification of important inflammatory molecules in poor immune responders
The results obtained in this small cohort study, are consistent with prior established findings regarding inflammation and immune activation in the setting of HIV. However, they also suggest that, while total inflammation does not precipitously drop off in those with optimized immune recovery on HAART vis-à-vis those with poor recovery, there is a distinct constellation of persistent immune activation and inflammation observed in those with poor immune recovery. We speculate that searching for and recognizing the individual components of this constellation early on after HAART initiation could have positive downstream effects, by creating a window for anti-inflammatory intervention in those with projected suboptimal immune recovery.
While individual comparisons failed to show that any of the proinflammatory markers differed significantly between groups on their own, some did appear, at viral suppression, to trend toward different median values and distributions between the two groups: the median concentration of BAFF is higher in the poor recovery group than the value of the third quartile of the good recovery group, and the data covers a much broader, higher range. A similar pattern is evident for APRIL. On the other hand, TNF-R1 has a much broader data range in the poor recovery group, but the median concentration is marginally higher in good immunologic responders. Thus, of the four cytokines in the second component, BAFF and APRIL exhibited the most promise in distinguishing poor from good immune responders.
The idea that some residual inflammation persists in HIVinfected patients has been thoroughly investigated by others; our results are consistent with this assumption, but suggest that the specific pattern of this inflammation is different depending on a patient's immune recovery status, specifically their CD4:CD8 ratio at the time of virological suppression. Thus far, our results predict that, of the most important markers of inflammation, that is, those Cytokine concentration (pg/ml) Fig. 1 . Boxplots comparing data range, including maximum, minimum, and IQR values, for cytokines where there was a visually discernible difference in median concentration between good and poor immune responders at viral suppression: IFN-c, IL-10, CD163, IFN-a2, IL-32, Osteopontin, BAFF, APRIL, CD14, TNF-R2, gp130, IL-6Ra, TNF-R1, Chitinase 3-like-1, IL-20, Osteocalcin, and IL-27 are depicted. None achieved statistically significant differences. IL-11, IL-26, IL-34, and MIP-1b are excluded because the difference between the medians and/or data ranges was negligible.
Cytokine concentration (pg/ml) ranking in the first two principal components, individuals with poor immune recovery at the time of viral suppression tend to be characterized by an inflammation profile with high BAFF and APRIL (median concentration is higher than the maximum observed value of good responders) and low gp130 and IL-6Ra (where the maximum observed concentration is less than the median value of the good responders).
Wada et al. demonstrated that in HIV-suppressed individuals on HAART, TNF-R2, BAFF, and CD14 were among the inflammatory biomarkers that remained elevated compared to in HIV-negative persons [3] . Our results go further to suggest that BAFF tends to be more elevated in those with poor immune recovery despite virological suppression compared to those with CD4:CD8 recovery P1 and viral suppression. This finding is of particular interest because the potential utility of BAFF as a serum biomarker has been explored by others; Carbone et al. found that the cytokine was ''independently associated with risk of AIDS after adjustment by clinical factors" [11] . Thus, our research brings together Wada et al.'s findings that this cytokine remains elevated in HIVsuppressed individuals with evidence linking it to poor immune recovery (and the poor outcomes associated with it) and other independent research linking BAFF with adverse outcomes [11] .
Conversely, TNF-R2 and CD14 tended to segregate preferentially toward those with good immune recovery, although they still registered at observable levels in the poor immune recovery group. TNF-R2 is a member of the TNF-R superfamily, that relates to the TNF superfamily, of which BAFF is a member. CD14 is a protein functioning in the translocation of microbiota across the gut wall, one mechanism thought to be driving persistent inflammation in virally suppressed patients [2, 3] . Due to the marginal difference between the two groups, and the intuitive notion that TNF-R2 should be upregulated similarly to BAFF considering their closely associated superfamilies and functions, we must remain skeptical of these findings. The association of CD14 with adverse clinical outcomes in a follow-up paper by Wada et al. further emphasizes this point. These cytokines should be measured again in a bigger cohort in order to test the present findings [8] .
We were also interested in how the inflammatory profiles of patients with poor or good immune recovery evolved over time, from the beginning of treatment through the achievement of viral suppression, and beyond. This information is of particular clinical importance, since it would, in theory, provide clinicians with the ability to predict early in the treatment course those patients who would likely reach optimal immune recovery and those who likely would not.
By using samples drawn from each patient at 4 separate visits, once at visit 1 before the initiation of treatment and at three later visits, occurring over the span of between one and two years, we were able to discern that five cytokines were, on average, observed in higher concentrations in the poor immune recovery group across the entire follow up period. Those cytokines were TNF-R1, APRIL, BAFF, CD163, and Osteopontin. Similarly, five cytokines were on average elevated across all four visits in the good recovery group: IL-6Ra, Chitinase 3-like-1, IFN-a2, IL-20, and Osteocalcin. The potential clinical implication is that, for example, a patient found to have high BAFF, TNF-R1, and APRIL, and comparatively low IL-6Ra and Chitinase 3-like-1 early on in treatment, will have a greater likelihood to have a poor immune recovery at one to two years, compared to a patient with the opposite results. If corroborated in additional larger studies, the detection of these biomarkers in newly-diagnosed patients could be utilized to prioritize individuals for future targeted anti-inflammatory interventions.
It is of note that two other biomarkers (including one from the first PCA component) were elevated preferentially in one group or the other at three out of four visits: CD14 was elevated in those with poor recovery at all visits except for visit 2; gp130 was ele- Fig. 3 . IPA-generated interaction pathway incorporating cytokines found to have higher means in the poor recovery group (compared to the good recovery group) across all 4 visits. TNF-R1 (TNFRSF1A), CD163, APRIL (TNFSF13), BAFF (TNFSF13B), and Osteopontin (SPP1) are represented on the network. Three of the above (APRIL, BAFF, and TNF-R1) were also sorted into the second principle component. Molecules from the input data set are highlighted in yellow. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) vated in the good group at all visits except for visit 2. This finding is interesting because these are two of the molecules that Wada et al. found to be detected at abnormal levels in virally suppressed persons when compared to HIV-negative persons [8] . In regards to CD14, Serrano-Villar et al. observed a negative correlation between this biomarker and CD4:CD8 [9] . Furthermore, a 2016 study associated unchanged concentrations of CD14 in virally suppressed HIV-infected people with serious non-AIDS events, including cardiovascular and renal disease, cirrhosis, non-AIDS-defining malignancies, and death [12] .
Pathway elucidation
IPA showed that the cytokines that were elevated across all four visits in the poor immune recovery group were all involved in some common pathways involving the pathogenesis of rheumatoid arthritis and cellular proliferation, as well as demonstrating modest overlap with the canonical pathway responsible for B and T cell differentiation. Given this finding, it is important to confirm with future investigations whether rheumatologic morbidities are more prevalent in poor immune responders compared to those with optimized CD4:CD8 counts.
Pathway elucidation for the inflammatory markers that were increased in the good recovery group was less impressive, as not all input molecules sorted cleanly into a single network or function; furthermore, less overlap with canonical pathways was observed.
We can speculate that these IPA results imply that systemic inflammation persists in both poor and good immune responders, but with different networks and molecules preferentially upregulated. The pathways associated with a poor response should, in future work, be mined for potential small molecules that modulate these activated immune pathways.
Limitations, conclusions, future directions
We were limited in our ability to produce far-reaching and generalizable results by our small, single-centre cohort. Furthermore, no genetic-level data is reported here. In addition, the ability to follow patients in a longitudinal study lasting for many years could enable us to directly correlate the observed inflammatory markers directly with clinical outcomes, or to confirm that poor immune recovery persists in the identified patients for longer than one to two years.
We surmise that there are differing inflammatory patterns to be observed in patients with poor immune recovery when poor immune recovery is defined as CD4:CD8 ratio <1 at the time of viral suppression, compared to those with good immune recovery (CD4:CD8 ratio P1) at that time. APRIL and BAFF are higher in those with poor recovery at the point of suppression but were also higher in this group at the onset of therapy and through three additional follow-up visits. In addition, TNF-R1, CD163, and Osteopontin were also in higher concentrations at the outset of therapy and beyond. These five molecules could thus see potential use in the future as biomarkers of likely poor immune recovery -Osteopontin, BAFF, and APRIL are likely to be the most important due to their high PCA ranking and consequently superior role in explaining variance in the data set. Simultaneously, we may expect to see IL-6Ra and Chitinase 3-like-1 register at lower concentrations than in other patients. These findings need to be validated in additional and larger cohorts, focusing on the particular molecules that ranked in high-priority principal components, and then subsequently determining whether this characteristic inflammation pattern has a role in causing poor immune recovery. If so, these molecules could serve as potential targets for adjunct therapies to HAART.
Finally, this study highlights the utility of using PCA to reveal results in a complex data set. The technique could be helpful in teasing out heretofore unrecognized aspects of the infection's pathogenesis.
